PUBLISHER: Persistence Market Research | PRODUCT CODE: 1926307
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1926307
Infectious Disease In-vitro Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2044
Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease in-vitro diagnostics market from 2025 to 2032. The infectious disease in-vitro diagnostics market is positioned for significant growth, with a projected CAGR of 4.7% from 2025 to 2032, indicating a market value increase from USD 46.6 billion in 2025 to USD 64.1 billion by 2032.
Key Insights:
- Infectious Disease In-vitro Diagnostics Market Size (2025E): USD 46.6 Bn
- Projected Market Value (2032F): USD 64.1 Bn
- Global Market Growth Rate (CAGR 2025 to 2032): 4.7%
Infectious Disease In-vitro Diagnostics Market - Report Scope:
Infectious disease in-vitro diagnostics (IVD) solutions play a critical role in detecting, monitoring, and managing infectious diseases through laboratory-based or point-of-care testing outside the human body. These diagnostics are essential in identifying pathogens such as bacteria, viruses, fungi, and parasites responsible for diseases including HIV, hepatitis, influenza, tuberculosis, malaria, and emerging viral infections. The market caters to hospitals, diagnostic laboratories, clinics, and decentralized healthcare settings with technologies such as molecular diagnostics, immunoassays, and rapid testing kits. Market expansion is fueled by rising global disease burden, increasing demand for early and accurate diagnosis, and advancements in diagnostic technologies enabling faster and more reliable testing.
Market Growth Drivers:
The global infectious disease in-vitro diagnostics market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and the rising need for rapid disease detection to prevent outbreaks. Increasing investments in healthcare infrastructure and laboratory capacity, especially in emerging economies, further accelerate market demand. Technological advancements such as PCR-based diagnostics, next-generation sequencing, and rapid antigen and molecular tests have significantly improved detection accuracy and turnaround times. Additionally, the growing use of point-of-care testing devices in decentralized settings and public health initiatives aimed at disease control and prevention continue to drive market growth. Heightened awareness following recent global pandemics has also strengthened diagnostic preparedness and surveillance systems worldwide.
Market Restraints:
Despite strong growth prospects, the infectious disease IVD market faces challenges associated with high diagnostic equipment costs, stringent regulatory requirements, and variability in reimbursement frameworks. Compliance with regulatory approvals and quality standards increases operational complexity and delays product launches. Limited healthcare infrastructure and affordability challenges in low-income regions restrict widespread adoption of advanced diagnostic solutions. Furthermore, concerns regarding test accuracy, false positives or negatives, and the need for skilled laboratory personnel also present obstacles to market expansion. Addressing these challenges requires coordinated efforts among healthcare authorities, manufacturers, and policymakers to ensure accessible and reliable diagnostics.
Market Opportunities:
The infectious disease in-vitro diagnostics market presents promising growth opportunities driven by technological innovation and evolving healthcare delivery models. The development of portable and rapid diagnostic devices enables testing in remote and resource-limited settings, improving access to healthcare services. Integration of digital health platforms, AI-driven diagnostic tools, and data analytics enhances disease monitoring and outbreak response capabilities. Expanding applications in antimicrobial resistance detection and personalized medicine also broaden market prospects. Strategic partnerships, investments in research and development, and the launch of cost-effective and user-friendly testing solutions will be critical for companies seeking to capitalize on future growth opportunities in the dynamic infectious disease diagnostics landscape.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the infectious disease in-vitro diagnostics market globally?
- Which technologies and test types are driving adoption across healthcare settings?
- How are technological advancements reshaping the competitive landscape of the infectious disease diagnostics market?
- Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global infectious disease in-vitro diagnostics market?
Competitive Intelligence and Business Strategy:
Leading players in the global infectious disease in-vitro diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on technological innovation, portfolio expansion, and strategic collaborations to maintain competitive advantage. Companies continue investing heavily in molecular diagnostic technologies and rapid testing platforms to meet growing global demand for accurate and timely detection. Partnerships with healthcare providers and government health agencies support widespread test deployment and improve access to diagnostics. Additionally, companies emphasize automation, digital integration, and scalable testing solutions to enhance laboratory efficiency and clinical outcomes in an increasingly dynamic healthcare environment.
Key Companies Profiled:
- QIAGEN
- Becton, Dickinson and Company
- bioMerieux SA
- F. Hoffmann-La Roche, Ltd.
- Hologic, Inc. (Gen Probe)
- Abbott
- Quidel Corporation
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- Danaher
- OraSure Technologies, Inc.
Infectious Disease In-vitro Diagnostics Industry Segmentation
By Product Type
- Instruments
- Reagents
- Software and Services
By Technology
- Immunoassay
- Molecular Diagnostics
- Microbiology
- Others
By Application
- MRSA
- Clostridium Difficile
- Respiratory Virus
- TB and Drug-resistant TB
- Gonorrhea
- HPV
- HIV
- Hepatitis C
- Hepatitis B
- COVID-19
- Others
By End User
- Point-of-care
- Central Laboratories
- Others
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Regulatory Landscape
- 3.2. Product Adoption Analysis
- 3.3. Value Chain Analysis
- 3.4. Key Deals and Mergers
- 3.5. PESTLE Analysis
- 3.6. Porter's Five Force Analysis
4. Global Infectious Disease In-vitro Diagnostics Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 4.3.3.1. Instruments
- 4.3.3.2. Reagents
- 4.3.3.3. Software and Services
- 4.3.4. Market Attractiveness Analysis: Product Type
- 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 4.4.3.1. Immunoassay
- 4.4.3.2. Molecular Diagnostics
- 4.4.3.3. Microbiology
- 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Technology
- 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 4.5.3.1. MRSA
- 4.5.3.2. Clostridium Difficile
- 4.5.3.3. Respiratory Virus
- 4.5.3.4. TB and Drug-resistant TB
- 4.5.3.5. Gonorrhea
- 4.5.3.6. HPV
- 4.5.3.7. HIV
- 4.5.3.8. Hepatitis C
- 4.5.3.9. Hepatitis B
- 4.5.3.10. COVID-19
- 4.5.3.11. Others
- 4.5.4. Market Attractiveness Analysis: Application
- 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 4.6.3.1. Point-of-care
- 4.6.3.2. Central Laboratories
- 4.6.3.3. Others
- 4.6.4. Market Attractiveness Analysis: End User
5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
6. North America Infectious Disease In-vitro Diagnostics Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Product Type
- 6.2.3. By Technology
- 6.2.4. By Application
- 6.2.5. By End User
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 6.4.1. Instruments
- 6.4.2. Reagents
- 6.4.3. Software and Services
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 6.5.1. Immunoassay
- 6.5.2. Molecular Diagnostics
- 6.5.3. Microbiology
- 6.5.4. Others
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 6.6.1. MRSA
- 6.6.2. Clostridium Difficile
- 6.6.3. Respiratory Virus
- 6.6.4. TB and Drug-resistant TB
- 6.6.5. Gonorrhea
- 6.6.6. HPV
- 6.6.7. HIV
- 6.6.8. Hepatitis C
- 6.6.9. Hepatitis B
- 6.6.10. COVID-19
- 6.6.11. Others
- 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 6.7.1. Point-of-care
- 6.7.2. Central Laboratories
- 6.7.3. Others
- 6.8. Market Attractiveness Analysis
7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Technology
- 7.2.4. By Application
- 7.2.5. By End User
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Rest of Europe
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 7.4.1. Instruments
- 7.4.2. Reagents
- 7.4.3. Software and Services
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 7.5.1. Immunoassay
- 7.5.2. Molecular Diagnostics
- 7.5.3. Microbiology
- 7.5.4. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 7.6.1. MRSA
- 7.6.2. Clostridium Difficile
- 7.6.3. Respiratory Virus
- 7.6.4. TB and Drug-resistant TB
- 7.6.5. Gonorrhea
- 7.6.6. HPV
- 7.6.7. HIV
- 7.6.8. Hepatitis C
- 7.6.9. Hepatitis B
- 7.6.10. COVID-19
- 7.6.11. Others
- 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 7.7.1. Point-of-care
- 7.7.2. Central Laboratories
- 7.7.3. Others
- 7.8. Market Attractiveness Analysis
8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Technology
- 8.2.4. By Application
- 8.2.5. By End User
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 8.4.1. Instruments
- 8.4.2. Reagents
- 8.4.3. Software and Services
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 8.5.1. Immunoassay
- 8.5.2. Molecular Diagnostics
- 8.5.3. Microbiology
- 8.5.4. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 8.6.1. MRSA
- 8.6.2. Clostridium Difficile
- 8.6.3. Respiratory Virus
- 8.6.4. TB and Drug-resistant TB
- 8.6.5. Gonorrhea
- 8.6.6. HPV
- 8.6.7. HIV
- 8.6.8. Hepatitis C
- 8.6.9. Hepatitis B
- 8.6.10. COVID-19
- 8.6.11. Others
- 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 8.7.1. Point-of-care
- 8.7.2. Central Laboratories
- 8.7.3. Others
- 8.8. Market Attractiveness Analysis
9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Technology
- 9.2.4. By Application
- 9.2.5. By End User
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 9.4.1. Instruments
- 9.4.2. Reagents
- 9.4.3. Software and Services
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 9.5.1. Immunoassay
- 9.5.2. Molecular Diagnostics
- 9.5.3. Microbiology
- 9.5.4. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 9.6.1. MRSA
- 9.6.2. Clostridium Difficile
- 9.6.3. Respiratory Virus
- 9.6.4. TB and Drug-resistant TB
- 9.6.5. Gonorrhea
- 9.6.6. HPV
- 9.6.7. HIV
- 9.6.8. Hepatitis C
- 9.6.9. Hepatitis B
- 9.6.10. COVID-19
- 9.6.11. Others
- 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 9.7.1. Point-of-care
- 9.7.2. Central Laboratories
- 9.7.3. Others
- 9.8. Market Attractiveness Analysis
10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Technology
- 10.2.4. By Application
- 10.2.5. By End User
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 10.4.1. Instruments
- 10.4.2. Reagents
- 10.4.3. Software and Services
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 10.5.1. Immunoassay
- 10.5.2. Molecular Diagnostics
- 10.5.3. Microbiology
- 10.5.4. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 10.6.1. MRSA
- 10.6.2. Clostridium Difficile
- 10.6.3. Respiratory Virus
- 10.6.4. TB and Drug-resistant TB
- 10.6.5. Gonorrhea
- 10.6.6. HPV
- 10.6.7. HIV
- 10.6.8. Hepatitis C
- 10.6.9. Hepatitis B
- 10.6.10. COVID-19
- 10.6.11. Others
- 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 10.7.1. Point-of-care
- 10.7.2. Central Laboratories
- 10.7.3. Others
- 10.8. Market Attractiveness Analysis
11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Technology
- 11.2.4. By Application
- 11.2.5. By End User
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 11.4.1. Instruments
- 11.4.2. Reagents
- 11.4.3. Software and Services
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 11.5.1. Immunoassay
- 11.5.2. Molecular Diagnostics
- 11.5.3. Microbiology
- 11.5.4. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 11.6.1. MRSA
- 11.6.2. Clostridium Difficile
- 11.6.3. Respiratory Virus
- 11.6.4. TB and Drug-resistant TB
- 11.6.5. Gonorrhea
- 11.6.6. HPV
- 11.6.7. HIV
- 11.6.8. Hepatitis C
- 11.6.9. Hepatitis B
- 11.6.10. COVID-19
- 11.6.11. Others
- 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 11.7.1. Point-of-care
- 11.7.2. Central Laboratories
- 11.7.3. Others
- 11.8. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2024
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. QIAGEN
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Becton, Dickinson and Company
- 12.3.3. bioMerieux SA
- 12.3.4. F. Hoffmann-La Roche, Ltd.
- 12.3.5. Hologic, Inc. (Gen Probe)
- 12.3.6. Abbott
- 12.3.7. Quidel Corporation
- 12.3.8. Siemens Healthineers AG
- 12.3.9. Bio-Rad Laboratories, Inc.
- 12.3.10. Danaher
- 12.3.11. OraSure Technologies, Inc.
- 12.3.12. Others
- 12.3.1. QIAGEN
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
